Acer Therapeutics
therapies for serious rare and life-threatening diseases with critical unmet medical need
Based in MA
AI Overview
With $380K in lobbying spend across 21 quarterly filings, Acer Therapeutics is an active lobbying client. Their lobbying covers 2 issue areas. Active from 2019 to 2023.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2019 | $60K |
| 2020 | $80K |
| 2021 | $80K |
| 2022 | $80K |
| 2023 | $80K |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Acer Therapeutics disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Pharmacy
orphan drug legislation, rare disease legislation, drug pricing policy
No specific legislative vehicles. Issues are, generally, orphan drug legislation, rare disease legislation, drug pricing policy
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.